Audit: QRS - Estrogen for Health & Longevity of the ER frontmatter

Audit conducted on 04/08/2026 15:28 using AI4L / Grok 4

Iterations

Summary

Items	Count
Total	91
Passed	82
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Medium coronary benefit retains conflicted marker from ER heading.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢
1.6	The QRS does not introduce new attributions.	🟢

---

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Clinical terms in benefits/gates match ER labels; at-a-glance uses plain wording.
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	At-a-glance plain phrasing is appropriate under 7.4; protocol/risks use clinical terms.

---

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Template # placeholders expanded to numbered marker/qualitative spans.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢

---

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No QRS section uses empty-state phrasing; empty speculative risks uses display:none per 13.5.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Benefit/risk titles and monitoring markers track ER labels.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	duration quoted because of colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	26.7.02
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	2026-0804-1354
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Grok
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	Grok 4
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

---

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Estrogen for Health & Longevity - Quick Reference Sheet
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	08/04/2026 from 2026-0804-1354
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Grok 4
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

---

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢
7.2	[at_a_glance] is no longer than 60 words	🟢	Exactly 60 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	e.g., skin-delivered, uterus-protecting hormone, hot flashes, clot risk.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

---

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢	Absolute/strong CIs plus pregnancy from populations who avoid.
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	e.g., recent MI or stroke retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	Stop items do not use ranking notation.
8.7	If no [stop_items] are present the section is left empty	N/A	Stop items are present.

---

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Eight interaction bullets; CIs excluded.
9.3	Individual [caution_items] are formatted as <li></li>	🟢
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drugs retained.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	Caution items do not use ranking notation.
9.7	If no [caution_items] are present the section is left empty	N/A	Caution items are present.

---

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Systemic dose; intact-uterus progestogen; initiation window.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three action sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢

---

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	VMS, bone density, genitourinary — match Practical Considerations.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered with high-tier benefits: VMS, bone/fracture, GSM.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three time sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	ER provides time-to-effect information.

---

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Title-level route/timing qualifiers retained for claim fidelity.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	“(conflicted)” is an ER evidence-status marker (⚠️ Conflicted), not an effect-size parenthetical.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers have items.

---

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_speculative has style=”display:none”.

---

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eight table biomarkers present.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	6–12 weeks then every 6–12 months.

---

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six qualitative markers listed.

Issues 04/08/2026 15:28

Pass rate 100.00%. No issues found.

Issues 04/08/2026 15:17

1. 1.3 — Coronary conflicted flag dropped: benefits_medium states “Favorable coronary outcomes when started early” without the ER heading’s “⚠️ Conflicted” marker, strengthening certainty relative to the source ER.

2. 12.3 — Mechanistic sleep/QoL phrasing: benefits_medium includes “improved sleep and quality of life via symptom control”; “via symptom control” is mechanistic elaboration beyond the key fact.

Fixes 04/08/2026 15:21

1. 1.3 — Coronary conflicted flag: Added “(conflicted)” after “Favorable coronary outcomes when started early” in benefits_medium to match the ER’s Conflicted marker.

2. 12.3 — Mechanistic sleep/QoL phrasing: Removed “via symptom control” from the medium sleep/quality-of-life benefit, leaving the key fact only.

Issues 04/08/2026 15:10

1. 1.1 — POI sub misstates ER: action_3_sub says “Premature ovarian insufficiency often continues to ~50–52 years,” but the ER states that replacement for premature ovarian insufficiency continues to ~50–52 years, not that POI itself continues.
2. 10.4 — action_3_sub inaccurate: Same span: used action_3_sub is not accurately derived from the ER Protocol/POI point and must state that replacement continues to ~50–52 years.

Fixes 04/08/2026 15:11

1. 1.1 / 10.4 — POI replacement wording: Corrected action_3_sub from “Premature ovarian insufficiency often continues to ~50–52 years” to “For premature ovarian insufficiency, replacement often continues to ~50–52 years,” matching the ER Protocol point.

Issues 04/08/2026 15:02

1. 7.4 — Unclear “with duration”: At-a-glance says “combined oral use raises breast cancer with duration”; “with duration” is clinical-register shorthand a non-specialist would not use unprompted. ER Conclusion uses “with longer use”.

Fixes 04/08/2026 15:03

1. 7.4 — Unclear “with duration”: Replaced at-a-glance “with duration” with ER Conclusion plain phrasing “with longer use”, and dropped “menopausal” before hot flashes to keep the summary at 60 words.

Issues 04/08/2026 14:52

1. 1.1 — Missing oral progesterone route: action_2_value says “Micronized progesterone 100–200 mg at night” without the ER Protocol’s “oral” route for systemic endometrial protection.
2. 1.2 — FSH target loses caution: marker_2_target (“May fall from high postmenopausal levels”) omits the ER Monitoring phrasing “may accompany adequate replacement”.
3. 2.7 — Jargon / unclear labels: time_1_label “Vasomotor relief” and time_3_label “Genitourinary” are specialist/incomplete; marker_6_target “HbA1c optimal” is unclear versus ER “HbA1c in optimal range per practitioner”.

Fixes 04/08/2026 14:53

1. 1.1 — Missing oral progesterone route: Updated action_2_value from “Micronized progesterone 100–200 mg at night” to “Oral micronized progesterone 100–200 mg at night” to match the ER Protocol route.
2. 1.2 — FSH target loses caution: Updated marker_2_target from “May fall from high postmenopausal levels” to “Falling levels may accompany adequate replacement” to restore the ER Monitoring cautious phrasing.
3. 2.7 — Jargon / unclear labels: Replaced time_1_label “Vasomotor relief” with “Hot flashes / night sweats”; time_3_label “Genitourinary” with “Vaginal / urinary symptoms”; and marker_6_target “HbA1c optimal” with “HbA1c in optimal range”.

Issues 04/08/2026 14:43

1. 1.1 — Incomplete progesterone marker target: marker_3_target says “Detectable if oral micronized used,” omitting “progesterone” from the ER Monitoring target.
2. 1.2 — FSH target loses caution: marker_2_target drops the ER’s “may accompany adequate replacement” cautious phrasing.
3. 2.7 — Unclear/unexpanded shorthand: action_3_value uses “<10 years post” without “menopause”; action_2_sub uses unexpanded “IUD”.

Fixes 04/08/2026 14:43

1. 1.1 — Incomplete progesterone marker target: Updated marker_3_target from “Detectable if oral micronized used” to “Detectable if oral micronized progesterone used” to match the ER Monitoring table.
2. 1.2 — FSH target loses caution: Updated marker_2_target from “Falling from high postmenopausal levels” to “May fall from high postmenopausal levels” to restore the ER’s cautious “may” phrasing.
3. 2.7 — Unclear/unexpanded shorthand: Expanded action_3_value “post” to “post-menopause” and action_2_sub “IUD” to “intrauterine device”.

Issues 04/08/2026 14:33

1. 1.1 — Unsupported monitoring dependency: At-a-glance claims effects depend on “monitoring”; ER Conclusion lists age, years since menopause, route, dose, companion hormone, clotting/breast risk, and goals, and separately supports monitored use rather than monitoring as a net-effect determinant.
2. 7.3 — At-a-glance fact support: Closing dependence clause is not backed by a distinct ER passage as worded (see 1.1).
3. 7.4 — At-a-glance plain language: Uses clinical-register “route” and bare “companion” instead of plain terms a non-specialist would use unprompted.

Fixes 04/08/2026 14:35

1. 1.1 / 7.3 — At-a-glance effect factors: Replaced unsupported “depend on … monitoring” with ER-aligned “age, how taken, dose, and personal risk,” matching Conclusion net-effect factors without inventing monitoring as a determinant.
2. 7.4 — At-a-glance plain language: Replaced bare “companion” with “hormone,” clinical-register “route” with “how taken,” and “clotting” with “clot,” keeping the summary within 60 words.

Issues 04/08/2026 14:21

1. 9.2 — Missing antihypertensive interaction: Key Interactions omits the ER bullet on additive blood-pressure or fluid effects with some antihypertensives (e.g., lisinopril, amlodipine).
2. 9.5 — Corticosteroid examples dropped: The corticosteroids/anticonvulsants item keeps phenytoin and phenobarbital but drops the ER example list for corticosteroids (prednisone, dexamethasone).

Fixes 04/08/2026 14:23

1. 9.2 — Missing antihypertensive interaction: Added Key Interaction item for antihypertensives with additive fluid effects (e.g., lisinopril, amlodipine), matching the ER Key Interactions bullet.
2. 9.5 — Corticosteroid examples restored: Restored ER example drugs prednisone and dexamethasone on the corticosteroids/anticonvulsants interaction item alongside phenytoin and phenobarbital.

Issues 04/08/2026 14:14

1. 1.2 — Cautious heart-outcome phrasing: At-a-glance says “favors better heart outcomes near menopause” instead of the ER Conclusion’s cautious “suggests more favorable heart outcomes when therapy begins near menopause.”
2. 1.3 — Strengthened exploratory claim: Same clause: “favors” strengthens the ER’s “suggests” for early-initiation cardiovascular outcomes.

Fixes 04/08/2026 14:15

1. 1.2 / 1.3 — Cautious heart-outcome phrasing: Changed at-a-glance “favors better heart outcomes” to “suggests better heart outcomes” to match the ER Conclusion’s cautious wording and avoid strengthening the claim.

Issues 04/08/2026 14:06

1. 1.2 — Cautious phrasing dropped: At-a-glance drops the ER Conclusion’s cautious “Exploratory evidence suggests more favorable heart outcomes…” and states a definitive “Heart outcomes favor starting near menopause.”

2. 1.3 — Heart claim strengthened: The same at-a-glance sentence strengthens an exploratory/suggestive ER claim into a definitive “favor,” which is not allowed.

Fixes 04/08/2026 14:08

1. 1.2 / 1.3 — At-a-glance heart claim: Restored ER cautious framing in at-a-glance: “Heart outcomes favor starting near menopause” → “Exploratory evidence favors better heart outcomes near menopause,” and trimmed the closing clause to stay within 60 words.

Issues 04/08/2026 14:01

1. 1.3 / 8.2 — Uncontrolled HTN as absolute stop: Uncontrolled hypertension is in the Contraindications stop gate, but the ER only lists it under populations who “typically avoid” systemic estrogen, not under Absolute/strong contraindications—strengthening avoid → absolute.

2. 2.7 — Unexpanded clinical jargon: VTE/PE and MI appear unexpanded in Contraindications; TBG and CV in Monitoring why-columns; DXA in Qualitative Assessment (inconsistent with plain “bone density scan” in Time to effect).

3. 2.15 — Colloquial at-a-glance phrasing: At-a-glance uses “Heart signals favor starting near menopause” instead of formal clinical wording aligned with the ER Conclusion (e.g., coronary/heart outcomes).

4. 7.4 — Specialist term in at-a-glance: Uses “estradiol” where plain-language “estrogen” is appropriate for the non-specialist at-a-glance test.

5. 9.4 — Thyroid interaction elaboration: Key Interactions thyroid item retains “(oral estrogen may raise levothyroxine requirements)” rather than the concise key fact only.

Fixes 04/08/2026 14:01

1. 1.3 / 8.2 — Uncontrolled HTN stop item: Removed “Uncontrolled hypertension” from Contraindications so stop_items match only Absolute/strong contraindications (plus pregnancy), not the ER’s softer “typically avoid” populations list.

2. 2.7 — Unexpanded clinical jargon: Expanded VTE/PE and MI in Contraindications; replaced CV/TG and TBG shorthand in Monitoring why-columns; replaced DXA with plain “bone-density scan” in Qualitative Assessment.

3. 2.15 — Colloquial at-a-glance phrasing: Changed “Heart signals favor” to “Heart outcomes favor” for formal clinical wording.

4. 7.4 — Specialist term in at-a-glance: Replaced “estradiol” with plain-language “estrogen” in at-a-glance.

5. 9.4 — Thyroid interaction elaboration: Shortened thyroid caution to “Thyroid hormone (levothyroxine)”, stripping the elaborative effect clause.